Real-world one year outcomes of a switch to aflibercept from ranibizumab in neovascular age related macular degeneration

被引：0
|
作者：
Citu, Maria Cristina [1 ,2 ]
Crosby-Nwaobi, Roxanne R. [1 ,2 ]
Eleftheriadou, Maria [1 ,2 ]
Vazquez-Alfageme, Clara [1 ,2 ]
Nicholson, Luke [1 ,2 ]
Sivaprasad, Sobha [1 ,2 ]
Hykin, Philip [1 ,2 ]
Hamilton, Robin D. [1 ,2 ]
机构：
[1] Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England
[2] UCL, Inst Ophthalmol, London, England
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2016年 / 57卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
3342
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Six-year outcomes in neovascular age-related macular degeneration with ranibizumab
    Julie Jacob
    Heidi Brié
    Anita Leys
    Laurent Levecq
    Filip Mergaerts
    Kris Denhaerynck
    Stefaan Vancayzeele
    Eline Van Craeyveld
    Ivo Abraham
    Karen Mac Donald
    [J]. International Journal of Ophthalmology, 2017, 10 (01) : 81 - 90
  • [42] One-Year Outcomes of Aflibercept in Recurrent or Persistent Neovascular Age-Related Macular Degeneration REPLY
    Arcinue, Cheryl A.
    Ma, Feiyan
    Barteselli, Giulio
    Sharpsten, Lucie
    Gomez, Maria Laura
    Freeman, William R.
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2015, 159 (05) : 997 - 997
  • [43] Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration
    Florian M. Heussen
    Qing Shao
    Yanling Ouyang
    Antonia M. Joussen
    Bert Müller
    [J]. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252 : 909 - 915
  • [44] Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration
    Heussen, Florian M.
    Shao, Qing
    Ouyang, Yanling
    Joussen, Antonia M.
    Mueller, Bert
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 252 (06) : 909 - 915
  • [45] Ranibizumab treat and extend for neovascular age-related macular degeneration (AMD) - One-year outcomes
    Trivedi, Dipti
    Alfaqawi, Fadi
    Lip, Peck Lin
    Mushtaq, Bushra
    Chavan, Randhir
    [J]. EYE, 2018, 32 (11) : 20 - 23
  • [46] Efficacy of Aflibercept in Treatment-naive Neovascular Age-related Macular Degeneration: Two-Year Real World Outcomes
    Eleftheriadou, Maria
    Vazquez-Alfageme, Clara
    Citu, Maria Cristina
    Crosby-Nwaobi, Roxanne R.
    Sivaprasad, Sobha
    Hykin, Philip
    Hamilton, Robin D.
    Patel, Praveen J.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [47] Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea
    Ryu, Gahyung
    Noh, Donghyoun
    Moon, Guihyun
    Sagong, Min
    [J]. CLINICAL OPHTHALMOLOGY, 2021, 15 : 3601 - 3611
  • [48] The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study
    Jeng, Yu-Ting
    Lai, Tso-Ting
    Lin, Chao-Wen
    Chen, Ta-Ching
    Hsieh, Yi-Ting
    Lin, Chang-Ping
    Ho, Tzyy-Chang
    Yang, Chung-May
    Yang, Chang-Hao
    [J]. PLOS ONE, 2022, 17 (07):
  • [49] Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
    Rachel Hui Fen Lim
    Bhaskar Gupta
    Peter Simcock
    [J]. International Journal of Ophthalmology, 2017, (03) : 423 - 426
  • [50] Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration
    Mantel, Irmela
    Gillies, Mark C.
    Souied, Eric H.
    [J]. SURVEY OF OPHTHALMOLOGY, 2018, 63 (05) : 638 - 645
12345